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Background
In the era of HAART C neoformans meningitis remains
one of the most important opportunistic infections asso-
ciated with HIV infection, with a high mortality (35-65%).
Case report
We present 3 cases of C neoformans meningitis occurred
in immunocompromised patients with advanced HIV
infection (CD4<50 cells/cmm) caused by strains with sus-
ceptibility to fluconazole dose-dependent and different
clinical course.
The first case: a 28 years old patient, confirmed with
HIV infection in 2009. He is diagnosed with systemic
infection with C neoformans with pneumonia, meningitis
and cutaneous cryptococcosis and a CD4<50 cells/cmm.
Blood and CSF cultures were positive for C neoformans.
CSF changes were minimal, but with high pressure. Was
treated with fluconazole - 1200 mg/day and lumbar
punctures were performed repeatedly. CSF cultures were
negative with difficulty, after about 8 weeks of treatment.
The evolution was unfavorable with neurocognitive dete-
rioration, seizures and death.
The second case: a 24 years old patient, diagnosed with
HIV infection in childhood, with a history of multiple
antiretroviral regimens but with discontinued treatment
two years ago is diagnosed with C neoformans meningitis
and a CD4<50 cells/cmm. CSF changes were minimal
and CSF pressure was increased. Under treatment with
liposomal amphotericin and lumbar punctures at 2-3
days intervals the evolution was slowly favorable. After 8
weeks of antifungal therapy the antiretroviral treatment
has been resumed.
The third case: a 54 years old patient with confirmed
HIV infection in 2011 is diagnosed with C neoformans
meningitis and a CD4<50 cells/cmm. CSF had significant
changes with incresed cellularity and low glycorrachia.
Treated with fluconazole – 1200 mg/day plus flucytosine –
the evolution was favorable.
Conclusion
We discussed the different factors that determine the
clinical course of C neoformans infection in HIV-infected
patients with advanced immunosuppression.
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